Endoskopie 2009; 18(3): 124-127

Use of Green Light in clinical and experimental urology

MUDr. Viktor Eret1, MUDr. Jiří Klečka Ph.D2, doc. MUDr. Milan Hora Ph.D2, MUDr. Petr Stránský1, MUDr. Petr Běhounek2
1 Urologická klinika FN a LF UK v Plzni
2 Urologická klinika, FN a LF UK, Plzeň

Introduction: This general article summarizes contemporary clinical opportunities of GreenLight (GL) laser in the treatment of benign

prostatic hyperplasia (BPH) and evaluates possible experimental using of the laser in partial nephrectomy. Our article is based on literature

data and paricularly on clinical and experimental work of authors. Technical data: Characteristics of GL are caused by its wavelenght

(532 nm) and power. Previous laser beam emited by 80 Watts (W) device on potassuim-titanyl-phosphate (KTP) crystal base was

recently replaced by 120 W device (HPS, high performance system) on lithium borate (LBO) crystal base. GL is nowadays the most applied

laser technology in the treatment of BPH, so-called photoselective evaporization of the prostate. Nevertheless transurethral resection

of the prostate (TUR-P) is still the gold standard of the treatment of BPH.

Conclusion: GL has a routine usage in the treatment of BPH, the

advantage of PVP compared with TUR-P is a minimalization of bleeding and TUR- syndrome, very short time or no time of leaving of the

permanent catheter and shorter hospitalization time. GL is an experimental method in other indications (kidney resection, stricture of

urethra, urinary bladder tumour) for the present.

Keywords: benign prostatic hyperplasia, laser, photoselective evaporization of the prostate, transurethral resection of the prostate, partial nephrectomy.

Published: October 16, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Eret V, Klečka J, Hora M, Stránský P, Běhounek P. Use of Green Light in clinical and experimental urology. Endoskopie. 2009;18(3):124-127.
Download citation

References

  1. Kuntzman RS, Malek RS, Barrett DM. High-power (60watt) potassium-titanyl-phosphate laser vaporization prostatectomy in living canines and in human and canine cadavers. Urology 1997; 49: 703-708. Go to original source... Go to PubMed...
  2. Malek RS, Barrett DM, Kutzmann RS. High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology 1998; 51: 254-256. Go to original source... Go to PubMed...
  3. Berry SJ, Coffey DS, Walsh PC. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479. Go to original source... Go to PubMed...
  4. AUA Practice Guidelines Committee: AUA guidline on management of benign prostatic hyperplasia (2003). Kapitola 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-547. Go to PubMed...
  5. Fitzpatrick JM, Mebust WK. Minimally invasive and endoscopic managementof benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, a kol. Campbells Urology. 8th Edition. Phildelphia: WB Saunders, 2002: 1379-1422.
  6. Smith JA jr. Urologic laser surgery. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, ads. Campbells Urology. 6th Edition. Philadelphia: WB Saunders, 1992: 2923-2941.
  7. Watson G, Murray S, Dretler SP, Parrish JA. The pulse-dye laser for fragmenting urinary calculi. J Urol 1987; 138: 195-198. Go to original source... Go to PubMed...
  8. Jung P, Wolffi JM, Mattelaer P, Jakse G. Role of lasertripsy in the manegement of ureteral calculi: Experience with Alexandrite laser systém in 232 patients. J Endourol 1996; 10: 345-348. Go to original source... Go to PubMed...
  9. Wollin TA, Denstedt JD. The holmium laser in urology. J Clin Med Surg 1998; 16: 13-20. Go to original source... Go to PubMed...
  10. Hai MA, Malek RS. Photoselective vaporization of the prostate: initial experience with a new 80 W KTP laser fot the treatment of benign prostatic hyperpasia. J Endourol 2003; 17: 93-96. Go to original source... Go to PubMed...
  11. Tooher R, Sutherland P, Costello A, et al. A Systematic Review of Holmium Laser Prostatectomy for Benign Prostatic Hyperplasia. J Urol 2004; 171: 1773-1781. Go to original source... Go to PubMed...
  12. Sandhu JS, Casey NG, Vanderbrink A, Egen C, Kaplan S. Highpower potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology 2004; 64(6): 1155-1159. Go to original source... Go to PubMed...
  13. Moinzadeh A, Gill IS, Rubenstein M, et al. Potassium-titanyl-phosphate laser laparoscopic partial nephrectomy without hilar clamping in the survival calf model. J Urol. 2005; 174: 1110-1114. Go to original source... Go to PubMed...
  14. Hindley RG, Barber NJ, Walsh K, et al. Laparoscopic partial nephrectomy using the potassium titanyl phosphate laser in a porcine model. Urology. 2006; 67: 1079-1083. Go to original source... Go to PubMed...
  15. Anderson KJ, Baker MR, Lindberg G, et al. Large-volume laparoscopic nephrectomy using potassium-titanyl-phosphate (KTP) laser in a survival porcine model. Eur Urol. 2007; 51: 749-754. Go to original source... Go to PubMed...
  16. Eret V, Hora M, Sýkora R, et al. GreenLight (532 nm) laser partial nephrectomy followed by the suture of the collecting system without renal hilar clamping in a porcine model. 2008, Urology. Epub ahead of print, doi:10.1016/j.urology.2008.03.011.
  17. Malloy TR. Emerging high-power KTP laser applications in urology. Contemp Urol 2005; 17: 30-37.
  18. Chapin BF, Eisner BH, Lahey S, et al. The use of KTP laser tumor ablation for treatment of bladder transitional cell carcinoma (initial results). Urology 2007; 70(Suppl 3A): 144. Go to original source...
  19. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU int 1999; 83: 227-231. Go to original source... Go to PubMed...
  20. Schatzl G, Madersbacher S, Djavan B, Lang T, Marberger M. Two yaers results of transurethral resection of the prostate versus four less invasive treatment options. Eur Urol 2000; 37: 695-701. Go to original source... Go to PubMed...
  21. Horninger W, Unterlechner H, Strasser H, Bartsch G. Transurethral prostatectomy: mortality and morbidity. Prostate 1996; 28: 195-201. Go to original source... Go to PubMed...
  22. Mebust WK, Holtgreve HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications: a comparative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-248. Go to original source... Go to PubMed...
  23. Tunuguntla HS, Evans CP. Minimaly invasive therapie for benign prostatic hyperplasia. World J Urol 2002; 20: 197-182. Go to original source...
  24. Shingleton WR, Terrel F, Renfroe L, Kolski J, Fowler JE. Lowpower v high power KTP laser: Improved method of laser ablation of prostate. J Endourol 1999; 13: 49-52. Go to original source... Go to PubMed...
  25. Te AE, Malloy TR, Stein BS, Ulchaker JC, hai MA, Nseyo UO, Malek RS. Photoselective laser vaporization of the prostate (PVP) for treatment of benign prostatic hyperplasia (BPH): The first results of United Statets multicentral prospective trial. J Urol 2004; 172: 1404-1408. Go to original source... Go to PubMed...
  26. Sulser T, Reich O, Wyler S, Ruszat R, Casella R, Hofstetter A, Bachmann A. Photoselective KTP laser vaporozation of the prostate: First Experience with 65 procedures. J Endourol 2004; 18(10): 976-981. Go to original source... Go to PubMed...
  27. Hoffman RM, Mac Donald R, Slaton JW, Wilt TJ. Laser prostatectomy versus transurethral resection fot treating benign prostatic obstruction: a systematic rewiev. J Urol, 2003; 169: 210-216. Go to original source... Go to PubMed...
  28. Klecka J, Hora M, Behounek P, et al. Our experience with 150 patients treated by photoselective vaporization of the prostate (PVP) in the Czech Republic. Urol 2007; 70(3 A suppl): 252. Go to original source... Go to PubMed...
  29. Rueter M. PVP Statistics, Laserscope internal communication.




Endoscopy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.